ArticleFrontiers in oncology2026
Distribution analysis of gynecological carcinomas with concurrent second primary carcinomas.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study investigates the distribution characteristics, occurrence time and clinicopathological correlations of second primary carcinoma (SPC) in patients with cervical carcinoma (CC) and endometrial carcinoma (EC) to guide precise monitoring. Materials and methods: This retrospective study analyzed 253 CC patients and 102 EC patients diagnosed with SPC at Fujian Cancer Hospital between April 2014 and April 2024. Descriptive statistical methods were employed to examine patient age, latency period, and clinicopathological characteristics. Additionally, a spatial distribution analysis of the anatomical sites of second primary cancers was conducted and visualized. Results: The median age at the initial diagnosis of CC and EC was 52 and 55 years, respectively. The median age of the SPC in CC and EC was 56 and 57.5 years; The median latency periods of SPC was 2 and 0.5 years. Among the CC patients who developed a SPC, 87.0% had cervical squamous cell carcinoma as the pathological type, and mainly in stages I-II(77.5%). The most common sites of SPC occurrence in CC were lung(25.3%), thyroid(22.5%), and breast(11.1%), and 69.1% are at stages I-II. Among the EC patients who developed a SPC, 87.3% have endometrioid adenocarcinoma as the pathological type, and 79.4% have been diagnosed at stage I-II. The SPC of EC mainly occurs in the thyroid(20.6%), ovary(16.7%), cervix(15.7%), and 82.4% occurs at stage I-II. Conclusion: This investigation on the occurrence of SPC following CC and EC uncovers distinct patterns in their locations and stages, profoundly influenced by their respective pathological types. These findings provide crucial insights for the re-examination of CC and EC, enabling earlier and more precise detection of SPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.